Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 5/20 | 0.60 |
| ▸ | ITGA2B | P08514 | 5/20 | 0.60 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.54 |
| ▸ | ACACB | O00763 | 1/20 | 0.52 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.51 |
| ▸ | TPH1 | P17752 | 2/20 | 0.48 |
| ▸ | SLC7A5 | Q01650 | 2/20 | 0.48 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | ALPI | P09923 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.46 |
| ▸ | XIAP | P98170 | 1/20 | 0.46 |
| ▸ | PPARG | P37231 | 2/20 | 0.46 |
| ▸ | PPARD | Q03181 | 1/20 | 0.45 |
| ▸ | GRB2 | P62993 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2923427 | 0.85 | PARP10 (0.58) | ITGB3ITGA2BACACBPTPN1TPH1 | |
| SCHEMBL2923430 | 0.85 | PARP10 (0.58) | ITGB3ITGA2BACACBPTPN1TPH1 | |
| SCHEMBL27654977 | 0.83 | ITGB3 (0.77) | ITGB3ITGA2BPTPN1TPH1SLC7A5 | |
| SCHEMBL7444460 | 0.82 | ITGB3 (0.72) | ITGB3ITGA2B | |
| SCHEMBL19528515 | 0.82 | ITGB3 (0.60) | ITGB3ITGA2BACACBPTPN1TPH1 | |
| SCHEMBL27674868 | 0.81 | ITGB3 (0.80) | ITGB3ITGA2BPTPN1TPH1SLC7A5 | |
| SCHEMBL2728563 | 0.80 | ITGB3 (0.69) | ITGB3ITGA2BPTPN1TPH1SLC7A5 | |
| SCHEMBL5026508 | 0.80 | ITGB3 (0.69) | ITGB3ITGA2BPTPN1TPH1SLC7A5 | |
| Hydrochloric Acid SCHEMBL6771655 | 0.79 | ITGB3 (0.68) | ITGB3ITGA2BPTPN1TPH1SLC7A5 | |
| SCHEMBL20400610 | 0.79 | ITGB3 (0.81) | ITGB3ITGA2BPTPN1TPH1SLC7A5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8354498-B2 | CD4 mimic peptides and their uses | COMMISSARIAT A L'ENERGIE ATOMIQUE (FR) | 2013-01-15 | — | — | US | claimed |
| EP-2035453-B1 | CD4 MIMIC PEPTIDES AND THEIR USES | COMMISSARIAT ENERGIE ATOMIQUE (FR) | 2010-09-29 | — | — | EP | claimed |
| US-20090285798-A1 | CD4 MIMIC PEPTIDES AND THEIR USES | COMMISSARIAT A L'ENERGIE ATOMIQUE (FR) | 2009-11-19 | — | — | US | claimed |
| EP-2035453-A2 | CD4 MIMIC PEPTIDES AND THEIR USES | COMMISSARIAT A L'ENERGIE ATOMIQUE (FR) | 2009-03-18 | — | — | EP | claimed |
| WO-2008010088-A2 | CD4 MIMIC PEPTIDES AND THEIR USES | COMMISSARIAT A L'ENERGIE ATOMIQUE (FR) | 2008-01-24 | — | — | WO | claimed |
| WO-2007144685-A1 | CD4 MIMIC PEPTIDES AND THEIR USES | COMMISSARIAT A L'ENERGIE ATOMIQUE (FR) | 2007-12-21 | — | — | WO | claimed |
| US-8354498-B2 | CD4 mimic peptides and their uses | COMMISSARIAT A L'ENERGIE ATOMIQUE (FR) | 2013-01-15 | — | — | US | disclosed |
| EP-2035453-B1 | CD4 MIMIC PEPTIDES AND THEIR USES | COMMISSARIAT ENERGIE ATOMIQUE (FR) | 2010-09-29 | — | — | EP | disclosed |
| US-20090285798-A1 | CD4 MIMIC PEPTIDES AND THEIR USES | COMMISSARIAT A L'ENERGIE ATOMIQUE (FR) | 2009-11-19 | — | — | US | disclosed |
| EP-2035453-A2 | CD4 MIMIC PEPTIDES AND THEIR USES | COMMISSARIAT A L'ENERGIE ATOMIQUE (FR) | 2009-03-18 | — | — | EP | disclosed |
| WO-2008010088-A2 | CD4 MIMIC PEPTIDES AND THEIR USES | COMMISSARIAT A L'ENERGIE ATOMIQUE (FR) | 2008-01-24 | — | — | WO | disclosed |
| WO-2007144685-A1 | CD4 MIMIC PEPTIDES AND THEIR USES | COMMISSARIAT A L'ENERGIE ATOMIQUE (FR) | 2007-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090285798-A1 | CD4 MIMIC PEPTIDES AND THEIR USES | CD4, HGFAC, GZMB | ITGB3 551/4885ITGA2B 414/4885NFE2L2 4837/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.